Multi-omics Advantage Position PrognomiQ’s proprietary multi-omics platform as a unique, scalable solution that combines proteomics with genomics and metabolomics to enable early disease detection, creating new opportunities to partner with healthcare systems, payers, and diagnostics developers seeking first-in-class tests.

Lung Cancer Focus Highlight the recent Series D funding and ProVue Lung launch as proof of market traction and clinical validation, targeting collaborations with hospitals, survivorship programs, and lung cancer screening initiatives to accelerate adoption and integration into existing screening workflows.

Strategic Partnerships Leverage the Allegheny Health Network, Penn Highlands Healthcare, and broader Seer collaboration to pursue co-development, data-sharing pilots, and translational studies that demonstrate real-world value to health systems and researchers.

Clinical Leadership Emphasize leadership appointments and medical strategy through the Chief Medical Officer and Independent Directors to engage clinical developers, CROs, and medical advisory boards for trial design, regulatory alignment, and evidence generation.

Growth and Scale Target mid-market and payer-affiliated networks by showcasing funding depth, rapid product deployment capabilities, and scalable proteomics technology to secure partnerships with diagnostic companies and health plans seeking cost-effective early-detection solutions.